Device Trial Radar · NCT07360158
BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
151
Planned (sponsor's estimate)
Start
Jun 22, 2026
Primary completion
May 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Biotronik SE & Co. KGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 22, 2026
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CorSky family is BIOTRONIK´s new generation of ICDs. They are the successor devices of the current Acticor/Rivacor family and inherit all iShock/iShock\_BC (Ilivia Neo, Intica Neo) implant and programmer software features. The new features of CorSky Family are either true novel BIOTRONIK ICD features or mainly driven by unification with the Amvia pacemaker family (Amvia Edge, -Sky). The goal of the study is to confirm the safety and performance of the CorSky Family of ICDs and CRT-Ds.
Conditions
- Tachyarrhythmia
- Heart Failure
Interventions
CorSky ICD or CRT-DDevice
Subjects with an indication for an ICD or CRT-D device will be implanted with a CorSky device of the CorSky ICD family according to standard implantation procedures. Device programming will be done according to the medical needs of the subjects.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CorSky-related SADE-d free rate at 6 monthsTime frame: 6 months
Locations
15 sites in 7 countries. Site status is shown where the registry gives one.
Medizinische Universität Graz
Graz, Styria, Austria · Recruiting
14 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.